ALMS: Envudeucitinib misses endpoints overall; strong IFNGS-high subgroup results
Envudeucitinib did not meet primary or secondary endpoints in the overall SLE population, but showed robust efficacy and a favorable safety profile in the IFNGS-high subgroup. Future development will focus there, with regulatory engagement planned by year-end.
Envudeucitinib did not meet primary or secondary endpoints in the overall SLE population, but showed robust efficacy and a favorable safety profile in the IFNGS-high subgroup.
Future development will focus on this biomarker-defined group, with regulatory engagement planned by year-end.Based on Alum…